Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy
Background Polypharmacy in hemodialysis patients can result in adverse patient outcomes. Deprescribing tools can reduce polypharmacy, yet no method exists for an outpatient hemodialysis population. Design Quality improvement study. Setting & Participants 240 patients in a tertiary-care outpatien...
Gespeichert in:
Veröffentlicht in: | American journal of kidney diseases 2017-11, Vol.70 (5), p.611-618 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 618 |
---|---|
container_issue | 5 |
container_start_page | 611 |
container_title | American journal of kidney diseases |
container_volume | 70 |
creator | McIntyre, Caitlin, Pharm D McQuillan, Rory, MD, MSc Bell, Chaim, MD, PhD Battistella, Marisa, Pharm D |
description | Background Polypharmacy in hemodialysis patients can result in adverse patient outcomes. Deprescribing tools can reduce polypharmacy, yet no method exists for an outpatient hemodialysis population. Design Quality improvement study. Setting & Participants 240 patients in a tertiary-care outpatient hemodialysis unit. Quality Improvement Plan We aimed to: (1) develop a deprescribing tool for target medications with poor evidence for efficacy and safety, (2) determine its effectiveness in decreasing polypharmacy, and (3) monitor patient safety and satisfaction. Outcomes The primary outcome was the proportion of target medications completely deprescribed after 4 weeks. Secondary outcomes were the proportion of target medications completely deprescribed after 6 months, average number of medications per patient before and after deprescription, and proportion of successful deprescriptions for each target medication. Measurements Number of medications deprescribed at 4 weeks and 6 months. Patient safety and satisfaction were monitored using drug-specific monitoring parameters. Results A deprescribing tool for specific medications was developed and implemented in the hemodialysis unit. 5 medication classes were selected: quinine, diuretics, α1 -blockers, proton pump inhibitors, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). All 240 patients in the unit were screened using the deprescribing tool. There were 171 of 240 (71%) patients prescribed at least 1 of the 5 target medications, and after applying the tool, 35 of 40 (88%) eligible patients had the medications deprescribed. There were 31 of 40 (78%) target medications completely deprescribed. 6 months after the study, only 5 of 31 (16%) medications discontinued were represcribed. At the end of the study, 57% of patients were taking fewer medications than at baseline. No adverse events were observed. Limitations Single-center study that relied on patient self-reporting of medication use and adherence to our recommendations. Conclusions Deprescribing tools can be applied successfully in an outpatient hemodialysis unit to reduce polypharmacy while maintaining patient safety and satisfaction. |
doi_str_mv | 10.1053/j.ajkd.2017.02.374 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1889386098</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0272638617305826</els_id><sourcerecordid>1889386098</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-10a335b59da63bafc4ebc345cf646c169a486ad6af62ab1257587e502c69f9f73</originalsourceid><addsrcrecordid>eNp9kctu1TAQhi0EoofCC7BAXrJJ8CVxHISQqnJppUoFtV1bE2dSfJpbbadS3oZn4clwdAoLFqw8i-__Nf6GkNec5ZyV8t0-h_1dmwvGq5yJXFbFE7LjpZCZ0lI_JTsmKpEpqdUReRHCnjFWS6WekyOhC66k4DsyX4O_xYgt_YSzx2C9a9x4S91IYaSXS5whOhwjPcNhah30a3CB3owuvqcnv35-X6B3caXnw-ynBxw28iou7UrjlBqtRwhIv039Ov8AP4BdX5JnHfQBXz2-x-Tmy-fr07Ps4vLr-enJRWaLqooZZyBl2ZR1C0o20NkCGyuL0naqUJarGgqtoFXQKQENF2VV6gpLJqyqu7qr5DF5e-hNi90vGKIZXLDY9zDitATDta6TGVbrhIoDav0UgsfOzN4N4FfDmdlMm73ZTJvNtGHCJNMp9Oaxf2kGbP9G_qhNwIcDgOmXDw69CTaZtNg6jzaadnL_7__4T9z2bnQW-jtcMeynxY_Jn-EmCMPM1Xbr7dS8kqzUafwNBlGmdw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1889386098</pqid></control><display><type>article</type><title>Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>McIntyre, Caitlin, Pharm D ; McQuillan, Rory, MD, MSc ; Bell, Chaim, MD, PhD ; Battistella, Marisa, Pharm D</creator><creatorcontrib>McIntyre, Caitlin, Pharm D ; McQuillan, Rory, MD, MSc ; Bell, Chaim, MD, PhD ; Battistella, Marisa, Pharm D</creatorcontrib><description>Background Polypharmacy in hemodialysis patients can result in adverse patient outcomes. Deprescribing tools can reduce polypharmacy, yet no method exists for an outpatient hemodialysis population. Design Quality improvement study. Setting & Participants 240 patients in a tertiary-care outpatient hemodialysis unit. Quality Improvement Plan We aimed to: (1) develop a deprescribing tool for target medications with poor evidence for efficacy and safety, (2) determine its effectiveness in decreasing polypharmacy, and (3) monitor patient safety and satisfaction. Outcomes The primary outcome was the proportion of target medications completely deprescribed after 4 weeks. Secondary outcomes were the proportion of target medications completely deprescribed after 6 months, average number of medications per patient before and after deprescription, and proportion of successful deprescriptions for each target medication. Measurements Number of medications deprescribed at 4 weeks and 6 months. Patient safety and satisfaction were monitored using drug-specific monitoring parameters. Results A deprescribing tool for specific medications was developed and implemented in the hemodialysis unit. 5 medication classes were selected: quinine, diuretics, α1 -blockers, proton pump inhibitors, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). All 240 patients in the unit were screened using the deprescribing tool. There were 171 of 240 (71%) patients prescribed at least 1 of the 5 target medications, and after applying the tool, 35 of 40 (88%) eligible patients had the medications deprescribed. There were 31 of 40 (78%) target medications completely deprescribed. 6 months after the study, only 5 of 31 (16%) medications discontinued were represcribed. At the end of the study, 57% of patients were taking fewer medications than at baseline. No adverse events were observed. Limitations Single-center study that relied on patient self-reporting of medication use and adherence to our recommendations. Conclusions Deprescribing tools can be applied successfully in an outpatient hemodialysis unit to reduce polypharmacy while maintaining patient safety and satisfaction.</description><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2017.02.374</identifier><identifier>PMID: 28416321</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adrenergic alpha-Antagonists - therapeutic use ; Adult ; Aged ; Aged, 80 and over ; Ambulatory Care ; Deprescribing ; Deprescriptions ; Diuretics - therapeutic use ; elderly ; end-stage renal disease (ESRD) ; Female ; hemodialysis (HD) ; Hemodialysis Units, Hospital ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Kidney Failure, Chronic - therapy ; Male ; medication optimization ; medication prescribing patterns ; Middle Aged ; Muscle Relaxants, Central - therapeutic use ; Nephrology ; Ontario ; outpatient HD ; patient safety ; pill burden ; Polypharmacy ; potentially inappropriate medications ; Proton Pump Inhibitors - therapeutic use ; Quality Improvement ; quality improvement activity ; Quinine - therapeutic use ; Renal Dialysis ; Tertiary Care Centers</subject><ispartof>American journal of kidney diseases, 2017-11, Vol.70 (5), p.611-618</ispartof><rights>National Kidney Foundation, Inc.</rights><rights>2017 National Kidney Foundation, Inc.</rights><rights>Copyright © 2017 National Kidney Foundation, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-10a335b59da63bafc4ebc345cf646c169a486ad6af62ab1257587e502c69f9f73</citedby><cites>FETCH-LOGICAL-c477t-10a335b59da63bafc4ebc345cf646c169a486ad6af62ab1257587e502c69f9f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.ajkd.2017.02.374$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28416321$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McIntyre, Caitlin, Pharm D</creatorcontrib><creatorcontrib>McQuillan, Rory, MD, MSc</creatorcontrib><creatorcontrib>Bell, Chaim, MD, PhD</creatorcontrib><creatorcontrib>Battistella, Marisa, Pharm D</creatorcontrib><title>Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><description>Background Polypharmacy in hemodialysis patients can result in adverse patient outcomes. Deprescribing tools can reduce polypharmacy, yet no method exists for an outpatient hemodialysis population. Design Quality improvement study. Setting & Participants 240 patients in a tertiary-care outpatient hemodialysis unit. Quality Improvement Plan We aimed to: (1) develop a deprescribing tool for target medications with poor evidence for efficacy and safety, (2) determine its effectiveness in decreasing polypharmacy, and (3) monitor patient safety and satisfaction. Outcomes The primary outcome was the proportion of target medications completely deprescribed after 4 weeks. Secondary outcomes were the proportion of target medications completely deprescribed after 6 months, average number of medications per patient before and after deprescription, and proportion of successful deprescriptions for each target medication. Measurements Number of medications deprescribed at 4 weeks and 6 months. Patient safety and satisfaction were monitored using drug-specific monitoring parameters. Results A deprescribing tool for specific medications was developed and implemented in the hemodialysis unit. 5 medication classes were selected: quinine, diuretics, α1 -blockers, proton pump inhibitors, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). All 240 patients in the unit were screened using the deprescribing tool. There were 171 of 240 (71%) patients prescribed at least 1 of the 5 target medications, and after applying the tool, 35 of 40 (88%) eligible patients had the medications deprescribed. There were 31 of 40 (78%) target medications completely deprescribed. 6 months after the study, only 5 of 31 (16%) medications discontinued were represcribed. At the end of the study, 57% of patients were taking fewer medications than at baseline. No adverse events were observed. Limitations Single-center study that relied on patient self-reporting of medication use and adherence to our recommendations. Conclusions Deprescribing tools can be applied successfully in an outpatient hemodialysis unit to reduce polypharmacy while maintaining patient safety and satisfaction.</description><subject>Adrenergic alpha-Antagonists - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Ambulatory Care</subject><subject>Deprescribing</subject><subject>Deprescriptions</subject><subject>Diuretics - therapeutic use</subject><subject>elderly</subject><subject>end-stage renal disease (ESRD)</subject><subject>Female</subject><subject>hemodialysis (HD)</subject><subject>Hemodialysis Units, Hospital</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Male</subject><subject>medication optimization</subject><subject>medication prescribing patterns</subject><subject>Middle Aged</subject><subject>Muscle Relaxants, Central - therapeutic use</subject><subject>Nephrology</subject><subject>Ontario</subject><subject>outpatient HD</subject><subject>patient safety</subject><subject>pill burden</subject><subject>Polypharmacy</subject><subject>potentially inappropriate medications</subject><subject>Proton Pump Inhibitors - therapeutic use</subject><subject>Quality Improvement</subject><subject>quality improvement activity</subject><subject>Quinine - therapeutic use</subject><subject>Renal Dialysis</subject><subject>Tertiary Care Centers</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctu1TAQhi0EoofCC7BAXrJJ8CVxHISQqnJppUoFtV1bE2dSfJpbbadS3oZn4clwdAoLFqw8i-__Nf6GkNec5ZyV8t0-h_1dmwvGq5yJXFbFE7LjpZCZ0lI_JTsmKpEpqdUReRHCnjFWS6WekyOhC66k4DsyX4O_xYgt_YSzx2C9a9x4S91IYaSXS5whOhwjPcNhah30a3CB3owuvqcnv35-X6B3caXnw-ynBxw28iou7UrjlBqtRwhIv039Ov8AP4BdX5JnHfQBXz2-x-Tmy-fr07Ps4vLr-enJRWaLqooZZyBl2ZR1C0o20NkCGyuL0naqUJarGgqtoFXQKQENF2VV6gpLJqyqu7qr5DF5e-hNi90vGKIZXLDY9zDitATDta6TGVbrhIoDav0UgsfOzN4N4FfDmdlMm73ZTJvNtGHCJNMp9Oaxf2kGbP9G_qhNwIcDgOmXDw69CTaZtNg6jzaadnL_7__4T9z2bnQW-jtcMeynxY_Jn-EmCMPM1Xbr7dS8kqzUafwNBlGmdw</recordid><startdate>20171101</startdate><enddate>20171101</enddate><creator>McIntyre, Caitlin, Pharm D</creator><creator>McQuillan, Rory, MD, MSc</creator><creator>Bell, Chaim, MD, PhD</creator><creator>Battistella, Marisa, Pharm D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20171101</creationdate><title>Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy</title><author>McIntyre, Caitlin, Pharm D ; McQuillan, Rory, MD, MSc ; Bell, Chaim, MD, PhD ; Battistella, Marisa, Pharm D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-10a335b59da63bafc4ebc345cf646c169a486ad6af62ab1257587e502c69f9f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adrenergic alpha-Antagonists - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Ambulatory Care</topic><topic>Deprescribing</topic><topic>Deprescriptions</topic><topic>Diuretics - therapeutic use</topic><topic>elderly</topic><topic>end-stage renal disease (ESRD)</topic><topic>Female</topic><topic>hemodialysis (HD)</topic><topic>Hemodialysis Units, Hospital</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Male</topic><topic>medication optimization</topic><topic>medication prescribing patterns</topic><topic>Middle Aged</topic><topic>Muscle Relaxants, Central - therapeutic use</topic><topic>Nephrology</topic><topic>Ontario</topic><topic>outpatient HD</topic><topic>patient safety</topic><topic>pill burden</topic><topic>Polypharmacy</topic><topic>potentially inappropriate medications</topic><topic>Proton Pump Inhibitors - therapeutic use</topic><topic>Quality Improvement</topic><topic>quality improvement activity</topic><topic>Quinine - therapeutic use</topic><topic>Renal Dialysis</topic><topic>Tertiary Care Centers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McIntyre, Caitlin, Pharm D</creatorcontrib><creatorcontrib>McQuillan, Rory, MD, MSc</creatorcontrib><creatorcontrib>Bell, Chaim, MD, PhD</creatorcontrib><creatorcontrib>Battistella, Marisa, Pharm D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McIntyre, Caitlin, Pharm D</au><au>McQuillan, Rory, MD, MSc</au><au>Bell, Chaim, MD, PhD</au><au>Battistella, Marisa, Pharm D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2017-11-01</date><risdate>2017</risdate><volume>70</volume><issue>5</issue><spage>611</spage><epage>618</epage><pages>611-618</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><abstract>Background Polypharmacy in hemodialysis patients can result in adverse patient outcomes. Deprescribing tools can reduce polypharmacy, yet no method exists for an outpatient hemodialysis population. Design Quality improvement study. Setting & Participants 240 patients in a tertiary-care outpatient hemodialysis unit. Quality Improvement Plan We aimed to: (1) develop a deprescribing tool for target medications with poor evidence for efficacy and safety, (2) determine its effectiveness in decreasing polypharmacy, and (3) monitor patient safety and satisfaction. Outcomes The primary outcome was the proportion of target medications completely deprescribed after 4 weeks. Secondary outcomes were the proportion of target medications completely deprescribed after 6 months, average number of medications per patient before and after deprescription, and proportion of successful deprescriptions for each target medication. Measurements Number of medications deprescribed at 4 weeks and 6 months. Patient safety and satisfaction were monitored using drug-specific monitoring parameters. Results A deprescribing tool for specific medications was developed and implemented in the hemodialysis unit. 5 medication classes were selected: quinine, diuretics, α1 -blockers, proton pump inhibitors, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). All 240 patients in the unit were screened using the deprescribing tool. There were 171 of 240 (71%) patients prescribed at least 1 of the 5 target medications, and after applying the tool, 35 of 40 (88%) eligible patients had the medications deprescribed. There were 31 of 40 (78%) target medications completely deprescribed. 6 months after the study, only 5 of 31 (16%) medications discontinued were represcribed. At the end of the study, 57% of patients were taking fewer medications than at baseline. No adverse events were observed. Limitations Single-center study that relied on patient self-reporting of medication use and adherence to our recommendations. Conclusions Deprescribing tools can be applied successfully in an outpatient hemodialysis unit to reduce polypharmacy while maintaining patient safety and satisfaction.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28416321</pmid><doi>10.1053/j.ajkd.2017.02.374</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0272-6386 |
ispartof | American journal of kidney diseases, 2017-11, Vol.70 (5), p.611-618 |
issn | 0272-6386 1523-6838 |
language | eng |
recordid | cdi_proquest_miscellaneous_1889386098 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Adrenergic alpha-Antagonists - therapeutic use Adult Aged Aged, 80 and over Ambulatory Care Deprescribing Deprescriptions Diuretics - therapeutic use elderly end-stage renal disease (ESRD) Female hemodialysis (HD) Hemodialysis Units, Hospital Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Kidney Failure, Chronic - therapy Male medication optimization medication prescribing patterns Middle Aged Muscle Relaxants, Central - therapeutic use Nephrology Ontario outpatient HD patient safety pill burden Polypharmacy potentially inappropriate medications Proton Pump Inhibitors - therapeutic use Quality Improvement quality improvement activity Quinine - therapeutic use Renal Dialysis Tertiary Care Centers |
title | Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T01%3A28%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20Deprescribing%20in%20an%20Outpatient%20Hemodialysis%20Unit:%20A%C2%A0Quality%20Improvement%20Study%20to%20Decrease%20Polypharmacy&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=McIntyre,%20Caitlin,%20Pharm%20D&rft.date=2017-11-01&rft.volume=70&rft.issue=5&rft.spage=611&rft.epage=618&rft.pages=611-618&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2017.02.374&rft_dat=%3Cproquest_cross%3E1889386098%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1889386098&rft_id=info:pmid/28416321&rft_els_id=S0272638617305826&rfr_iscdi=true |